Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study

2021 ◽  
Vol 20 (6) ◽  
pp. 426-436 ◽  
Author(s):  
Karl Georg Haeusler ◽  
Paulus Kirchhof ◽  
Claudia Kunze ◽  
Serdar Tütüncü ◽  
Cornelia Fiessler ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Multicentre Study ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Open Label ◽  
Systematic Monitoring

Endovascular thrombectomy in patients with acute ischaemic stroke and atrial fibrillation: a MR CLEAN subgroup analysis

2017 ◽  
Vol 13 (8) ◽  
pp. 996-1002 ◽  
Author(s):  
Alis Heshmatollah ◽  
Puck Fransen ◽  
Olvert Berkhemer ◽  
Debbie Beumer ◽  
Aad van der Lugt ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Subgroup Analysis ◽  
Endovascular Thrombectomy ◽  
Mr Clean

Acute Ischaemic Stroke and Atrial Fibrillation—Does Time, Location and Severity Matter?

2008 ◽  
Vol 17 ◽  
pp. S86-S87
Author(s):  
Martin Brown ◽  
William O’Brien ◽  
Tommy Wong ◽  
Maged Willaim ◽  
Scott Whyte ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke

Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation

2016 ◽  
Vol 116 (09) ◽  
pp. 410-416 ◽  
Author(s):  
Maurizio Paciaroni ◽  
Giancarlo Agnelli ◽  
Walter Ageno ◽  
Valeria Caso
Keyword(s):  
Atrial Fibrillation ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Substantial Reduction ◽  
Anticoagulation Therapy ◽  
Early Recurrence ◽  
Optimal Time ◽  
Optimal Timing ◽  
Stroke Patients ◽  
Haemorrhagic Transformation

SummaryIn patients with acute stroke and atrial fibrillation (AF), the risk of early recurrence has been reported to range between 0.1% and 1.3% per day. Anticoagulants are the most effective therapy for the prevention of recurrent ischaemic stroke in these patients, but randomised clinical trials have failed to produce any evidence supporting the administration of heparin within 48 hours from stroke onset as it has been associated with a non-significant reduction in the recurrence of ischaemic stroke, no substantial reduction in death and disability, and an increase in intracranial bleeding. As early haemorrhagic transformation is a major concern in the acute phase of stroke patients with AF, determining the optimal time to start anticoagulant therapy is essential. This review which focuses on the epidemiology of recurrent ischaemic stroke and haemorrhagic transformation in patients with acute ischaemic stroke and AF, proposes a model for decision making on optimal timing for initiating anticoagulation, based on currently available evidence.

Sign in / Sign up

Export Citation Format

Share Document